Ascendis Pharma A/S (NASDAQ:ASND) Releases Earnings Results, Beats Expectations By $0.11 EPS

Ascendis Pharma A/S (NASDAQ:ASND) released its quarterly earnings data on Thursday, May 7th. The biotechnology company reported $0.32 earnings per share for the quarter, beating the consensus estimate of $0.21 by $0.11, Zacks reports. The business had revenue of $285.45 million for the quarter, compared to the consensus estimate of $362.47 million.

Here are the key takeaways from Ascendis Pharma A/S’s conference call:

• FDA approval of a third TransCon product (YUVIWEL/TransCon CNP) for achondroplasia, with early U.S. uptake of more than 60 children prescribed within weeks and plans for selected international early access and an EU decision expected in Q4 2026.
• Q1 revenue totaled €247M (company cited ~€197M from its lead rare‑endocrine product and €44M from SKYTROFA), with operating profit €25M (10% margin), non‑IFRS net profit €18M, €573M cash on hand, a completed Nasdaq direct listing, redemption of convertible notes, and an agreed PRV sale for $187.5M.
• The Phase II COACH data for the TransCon CNP + TransCon hGH combination showed substantially greater Week‑52 efficacy versus monotherapy (height Z‑score, limb alignment, spinal canal and arm‑span improvements), which management says could reduce or eliminate the need for invasive limb/spine surgeries.
• Management decided to discontinue internal oncology development of TransCon IL‑2 β/γ despite encouraging Phase I/II signals, signaling a strategic pullback from oncology and potential loss of internal upside for that program.

Ascendis Pharma A/S Stock Down 1.8%

NASDAQ:ASND traded down $4.39 on Wednesday, hitting $235.26. 353,253 shares of the company’s stock were exchanged, compared to its average volume of 686,120. The firm has a 50-day moving average price of $233.31 and a 200-day moving average price of $222.54. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.00 and a quick ratio of 0.72. Ascendis Pharma A/S has a 52 week low of $156.56 and a 52 week high of $250.74. The company has a market cap of $14.68 billion, a P/E ratio of 27.13 and a beta of 0.41.

Insider Buying and Selling at Ascendis Pharma A/S

In other news, insider Flemming Steen Jensen sold 19,460 shares of the firm’s stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $238.49, for a total value of $4,641,015.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 40.00% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of ASND. Advisory Services Network LLC bought a new stake in shares of Ascendis Pharma A/S during the 3rd quarter worth approximately $26,000. Arax Advisory Partners grew its stake in shares of Ascendis Pharma A/S by 212.2% in the fourth quarter. Arax Advisory Partners now owns 153 shares of the biotechnology company’s stock valued at $33,000 after buying an additional 104 shares in the last quarter. Global Retirement Partners LLC increased its holdings in Ascendis Pharma A/S by 111.9% during the fourth quarter. Global Retirement Partners LLC now owns 214 shares of the biotechnology company’s stock worth $46,000 after buying an additional 113 shares during the last quarter. GW&K Investment Management LLC raised its position in Ascendis Pharma A/S by 75.2% during the fourth quarter. GW&K Investment Management LLC now owns 226 shares of the biotechnology company’s stock worth $48,000 after acquiring an additional 97 shares in the last quarter. Finally, Quadrant Capital Group LLC bought a new stake in Ascendis Pharma A/S during the third quarter worth $74,000.

Analyst Ratings Changes

ASND has been the topic of a number of research reports. Wells Fargo & Company cut their price target on shares of Ascendis Pharma A/S from $330.00 to $326.00 and set an “overweight” rating on the stock in a research note on Friday, May 8th. Cantor Fitzgerald reissued an “overweight” rating and set a $300.00 price objective on shares of Ascendis Pharma A/S in a research report on Monday, March 2nd. The Goldman Sachs Group restated a “buy” rating and set a $255.00 price objective on shares of Ascendis Pharma A/S in a report on Monday, March 2nd. Wedbush reaffirmed an “outperform” rating and issued a $273.00 price objective on shares of Ascendis Pharma A/S in a research report on Thursday, April 9th. Finally, Bank of America upped their target price on shares of Ascendis Pharma A/S from $262.00 to $292.00 and gave the stock a “buy” rating in a research note on Thursday, April 16th. Two analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $295.39.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.